Search Results for “research” – Page 37 – media

2.5 billion+2.3 billion! Sanofi adds more nuclear weapons

Original Xie Ling Arterial New Medicine October 18, 2024 08:27 Chongqing Yesterday (October 17th), Sanofi announced that it has reached an agreement with Orano Med, a subsidiary of the Orano Group, to further accelerate the development of next-generation radioligand therapy (RLT) by leveraging their expertise in combating rare cancers. According to the agreement, Sanofi and Oueno will jointly invest in a new entity operated under the Oueno Medical brand, focusing on the discovery, design, and clinical development of next-generation radioligand therapy (RLT) based on lead-212 (①¹² Pb) alpha emitting isotopes. Sanofi will make an equity investment of 300 million euros (approximately 2.313 billion yuan), accounting for approximately 16% of the equity of the new entity Orano Medical, with a valuation of 1.9 billion euros (approximately 14.648 billion yuan). At the beginning of last month, Sanofi announced a licensing agreement with RadioMedix and Orano Med for RLT, focusing on AlphaMedix, a ...
- Source: drugdu
- 85
- October 21, 2024
Large pharmaceutical companies, change of controlling shareholders

On October 17, Zhejiang Inter Group issued the “Indicative Announcement on the Change of Controlling Shareholders and Exemption from the Offer for this Transaction”. Huachen Investment transferred nearly 122 million shares of Inter Group held by it to Zhejiang Pharmaceutical and Health Industry Group, the controlling shareholder of Huachen Investment, free of charge; at the same time, Zhejiang International Trade Group entrusted the voting rights corresponding to nearly 151 million shares of Inter Group held by it to Zhejiang International Trade’s wholly-owned subsidiary Zhejiang Pharmaceutical Group for exercise. After this change of rights and interests, Zhejiang Pharmaceutical Group can actually control the voting rights corresponding to nearly 322 million shares of Inter Group. As of September 30, 2024, it accounts for 61.67% of Inter Group’s total share capital. So far, the controlling shareholder of Inter Group has changed from Zhejiang International Trade to Zhejiang Pharmaceutical Group, and the actual controller ...
- Source: drugdu
- 68
- October 21, 2024
Countdown to the 2024 medical insurance negotiations, these drugs are the focus

According to multiple sources in the industry, from October 16 to 18, the National Medical Insurance Administration conducted pre-negotiations with companies that passed expert reviews. As in last year, “pre-negotiations” give companies ample opportunities for communication. Before the formal negotiations, the National Medical Insurance Administration specially organized experts and companies that intend to participate in the negotiations to fully communicate around the payment standard calculations for the intended negotiated products. The medical insurance party and the enterprise party first go through a round of “pre-negotiations” before the formal negotiations, which can facilitate the enterprise party to more fully understand the negotiation rules, and when the formal negotiations are held, the results will be relatively ideal. Previously, the National Medical Insurance Administration had organized fund calculations and pharmacoeconomic calculations in Xiaotangshan, Beijing. On September 19, the National Medical Insurance Administration held an on-site communication meeting for companies to negotiate/bid in Beijing. ...
- Source: drugdu
- 71
- October 21, 2024
Huawei enters the hot track of medical devices

Recently, the website of the State Intellectual Property Office updated a new invention patent, named “Method for controlling stimulator, stimulator, brain-computer interface system and chip”, and the inventor of the patent is Huawei Technologies Co., Ltd. It is reported that this is Huawei’s second brain-computer interface related patent. As early as June 2023, Huawei announced a patent called “A brain-computer interface device and information acquisition method”. Brain-computer interface is one of the most popular phenomenal technologies in recent years, and its potential in the medical field is highly expected by the industry. According to McKinsey’s calculations, the potential market size of global brain-computer interface medical applications is expected to reach US$40 billion in 2030, and it is expected to exceed the US$145 billion mark by 2040. With the increase in R&D investment, the medical application of brain-computer interface has gradually shifted from early abstract concepts to landing results. In September, ...
- Source: drugdu
- 72
- October 21, 2024
The National Medical Insurance Administration issued a document! Special governance is being carried out nationwide

On October 16, the National Medical Insurance Administration issued the “Notice of the Office of the National Medical Insurance Administration on Standardizing the Management of Prescriptions for Medical Insurance Drugs Outside the Hospital”, proposing to carry out special governance on the use of prescriptions outside the hospital. Before the end of December 2024, special inspections will be carried out on prescription drugs for outpatient chronic diseases and special diseases, urban and rural residents’ outpatient “two diseases” medication mechanism, and other prescription drugs with high amounts, high costs, and high risks of fraud and insurance fraud. The National Medical Insurance Administration requires that, relying on big data analysis, paper prescriptions with large usage must be checked, single prescriptions with large dosages must be checked, repeated prescriptions of the same insured person must be checked, single designated medical institutions with large paper prescriptions must be checked, and key departments with large prescriptions ...
- Source: drugdu
- 67
- October 21, 2024
The National Medical Insurance Administration issued a document! Special governance is being carried out nationwide

On October 16, the National Medical Insurance Administration issued the “Notice of the Office of the National Medical Insurance Administration on Standardizing the Management of Prescriptions for Medical Insurance Drugs Outside the Hospital”, proposing to carry out special governance on the use of prescriptions outside the hospital. Before the end of December 2024, special inspections will be carried out on prescription drugs for outpatient chronic diseases and special diseases, urban and rural residents’ outpatient “two diseases” medication mechanism, and other prescription drugs with high amounts, high costs, and high risks of fraud and insurance fraud. The National Medical Insurance Administration requires that, relying on big data analysis, paper prescriptions with large usage must be checked, single prescriptions with large dosages must be checked, repeated prescriptions of the same insured person must be checked, single designated medical institutions with large paper prescriptions must be checked, and key departments with large prescriptions ...
- Source: drugdu
- 81
- October 19, 2024
RNA editing pioneers fought a comeback

This is the title of an article published in Nauter in February this year (Move over, CRISPR: RNA-editing therapies pick up steam). RNA editing technology, which is coming to the fore, is seen as a potential to surpass CRISPR due to its safer and more flexible characteristics. The technology is in its infancy, and the bets of MNCs such as Eli Lilly and GSK have once pushed its popularity to a climax. However, Wave, an RNA editing pioneer founded in 2012, took more than 10 years to push its first RNA editing project WVE-006 into clinical trials. During this period, due to the clinical failure of other nucleic acid drugs, Wave’s stock price fell from a high of US$56 per share to around US$1 per share, and market expectations were no longer met. After years of silence, a counterattack driven by clinical data is taking place. On October 16, Wave ...
- Source: drugdu
- 77
- October 19, 2024
Suda Testing participates in the release of ESG standards for medical device companies, promoting sustainable development in the industry

On the morning of October 14, sponsored by the “the Belt and Road” Life Science and Technology Promotion Alliance, and jointly organized by the Shenzhen Life Science and Technology Industry University Research Capital Alliance, Suzhou Suda Health and Environmental Technology Research Institute Co., Ltd., Shenzhen Huada Intelligent Manufacturing Technology Co., Ltd., and Jiewen (Shenzhen) Technology Services Co., Ltd., the ESG standard seminar for the medical device industry was successfully held in Shenzhen. The purpose of this seminar is to jointly explore the current situation and challenges of ESG standards in the medical device industry, promote the formulation and implementation of standards, and enhance the industry’s international competitiveness and sustainable development capabilities. At the beginning of the meeting, relevant leaders from the Standards Department of Shenzhen Municipal Market Supervision Administration, Suzhou Medical Device Industry Development Group Co., Ltd., the “the Belt and Road” Life Technology Promotion Alliance, and Suzhou Suda Health ...
- Source: drugdu
- 75
- October 19, 2024
2.5 billion! Haoluo Jie has obtained the world’s only uterine ablation product

On October 15th, Hologic Corporation (hereinafter referred to as Hologic) announced that it had reached a final acquisition agreement with Gynesonics for approximately $350 million (approximately RMB 2.5 billion). With this acquisition, Haoluo Jie will further expand its layout in women’s health products to consolidate its leading position in global women’s health. Acquiring innovative products The Gynesonics company acquired this time is an innovative women’s healthcare company headquartered in California, USA. Since its establishment in 2005, we have been committed to providing safe and effective minimally invasive treatment solutions for women with symptomatic uterine fibroids. The Sonata system, the core product of Gynesonics, is the world’s first and only FDA approved diagnostic intrauterine imaging device that can treat specific symptomatic uterine fibroids, including fibroids associated with severe menstrual bleeding, through the cervix. This is also the purpose of Haoluo Jie’s huge investment in acquisition.  The Sonata system consists of ...
- Source: drugdu
- 66
- October 19, 2024
A medical device enters the innovation channel

Recently, the Shanghai Medical Products Administration announced that in accordance with the requirements of the “Special Review Procedure for Class II Innovative Medical Devices in Shanghai”, the Shanghai Medical Products Administration has organized relevant experts to review the special review application for Class II innovative medical devices in the city, and intends to agree to allow Shanghai Futuo Zhida Medical Technology Co., Ltd. (hereinafter referred to as “Futuo Zhida”) to enter the special review procedure for its disposable pulmonary nodule three-dimensional identification positioning marker. Developing innovative technologies with AR navigation systems Founded in 2018, Futo Zhida is a subsidiary of Fosun Pharma, focusing on innovative medical devices and surgical development. Its team has rich experience and a global perspective in the development of image navigation algorithms, intervention consumables design, and production. According to the Chinese Journal of Tuberculosis and Respiratory Sciences, the incidence rate and mortality of lung cancer rank ...
- Source: drugdu
- 64
- October 18, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.